By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


SEARCH JOBS

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.


Key Statistics


Email: jobs@revance.com
Ownership: Public

Web Site: Revance
Employees: 100+
Symbol: RVNC
 









Company News
Revance (RVNC) Releases Second Quarter 2016 Results 8/5/2016 10:41:27 AM
Revance (RVNC) To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 7/22/2016 7:43:48 AM
Revance (RVNC) Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines 7/15/2016 11:18:51 AM
Revance (RVNC) Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors 7/5/2016 8:06:20 AM
Once Floated as Allergan (AGN) Target, Revance (RVNC)'s Stock Drops as Crow’s Feet Drug Fails Trial 6/14/2016 9:15:59 AM
Revance Therapeutics, Inc. (RVNC) To Release Fourth Quarter And Full Year 2015 Financial Results Wednesday, March 2, 2016 2/18/2016 8:19:27 AM
Revance Therapeutics, Inc. (RVNC) Specifies 2016 Clinical Program Milestones 1/8/2016 7:58:58 AM
Revance Therapeutics, Inc. (RVNC) Appoints Abhay Joshi, PhD, as Chief Operating Officer 12/15/2015 8:30:55 AM
Revance Therapeutics (RVNC) To Present In The 27th Annual Piper Jaffray Healthcare Conference 11/20/2015 8:03:33 AM
Revance Therapeutics (RVNC) Releases Third Quarter 2015 Results 11/10/2015 7:58:19 AM
1234567
//-->